CeriBell (NASDAQ:CBLL) CTO Sells $226,965.76 in Stock
by Doug Wharley · The Cerbat GemCeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CTO Raymond Woo sold 11,104 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $20.44, for a total value of $226,965.76. Following the transaction, the chief technology officer directly owned 197,648 shares in the company, valued at approximately $4,039,925.12. The trade was a 5.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Raymond Woo also recently made the following trade(s):
- On Wednesday, April 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The stock was sold at an average price of $18.56, for a total value of $206,238.72.
- On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The stock was sold at an average price of $18.25, for a total value of $147,587.75.
- On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total transaction of $13,951.95.
CeriBell Stock Performance
Shares of NASDAQ CBLL opened at $20.15 on Thursday. The firm’s 50-day moving average price is $19.16 and its 200-day moving average price is $18.66. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33. The company has a market cap of $763.08 million, a PE ratio of -13.71 and a beta of 0.99. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13.
CeriBell (NASDAQ:CBLL – Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The firm had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. As a group, analysts anticipate that CeriBell, Inc. will post -1.44 EPS for the current year.
Analysts Set New Price Targets
Several research firms have recently weighed in on CBLL. BTIG Research reissued a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CeriBell in a research report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, CeriBell currently has an average rating of “Moderate Buy” and an average price target of $23.20.
Check Out Our Latest Report on CBLL
Institutional Trading of CeriBell
Several large investors have recently added to or reduced their stakes in CBLL. Strs Ohio purchased a new stake in CeriBell during the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd grew its position in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of CeriBell in the 3rd quarter worth $33,000. CWM LLC increased its stake in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the period.
CeriBell Company Profile
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.